We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
-$114M
Cap. Flow
+$174M
Cap. Flow %
6.13%
Top 10 Hldgs %
45.99%
Holding
98
New
13
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
BMEA icon
Biomea Fusion
BMEA
+$36.9M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$24.8M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$21.3M
4
GHRS icon
GH Research
GHRS
+$20.7M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$20.6M

Top Sells

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$27.2M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$10.3M
3
VINCU
Vincerx Pharma, Inc. Unit
VINCU
+$8.1M
4
ACHL
Achilles Therapeutics
ACHL
+$2.6K

Sector Composition

Rank Sector Weight
1 Healthcare 97.6%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
76
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.26M 0.19%
500,000
– –
RACB
77
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.07M 0.18%
500,000
– –
PANA
78
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$5.01M 0.18%
+500,000
New +$5.01M
JYAC
79
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.97M 0.18%
500,000
– –
MLTX icon
80
MoonLake Immunotherapeutics
MLTX
$1.57B
$4.13M 0.15%
400,000
– –
OBIO icon
81
Orchestra BioMed
OBIO
$238M
$4.08M 0.14%
400,000
– –
KNSA icon
82
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.05M 0.14%
290,577
– –
SYRE icon
83
Spyre Therapeutics
SYRE
$8.54B
$3.83M 0.14%
22,000
– –
LJPC
84
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.81M 0.13%
890,700
– –
ATXS
85
DELISTED
Astria Therapeutics
ATXS
$3.75M 0.13%
+295,833
New +$3.84M
ORIC icon
86
Oric Pharmaceuticals
ORIC
$1.15B
$3.54M 0.12%
200,000
– –
GNCA
87
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.65M 0.09%
1,134,453
– –
CHFW.U
88
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.04M 0.07%
200,000
– –
TARA icon
89
Protara Therapeutics
TARA
$220M
$2.04M 0.07%
209,227
– –
SNCE
90
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2M 0.07%
10,000
– –
OMEG
91
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.99M 0.07%
200,000
– –
CLRB icon
92
Cellectar Biosciences
CLRB
$20.5M
$1.09M 0.04%
3,067
– –
BOLT icon
93
Bolt Biotherapeutics
BOLT
$7.67M
$773K 0.03%
2,500
– –
NUVB.WS
94
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$693K 0.02%
266,666
– –
ZGNX
95
DELISTED
Zogenix, Inc.
ZGNX
$472K 0.02%
27,300
– –
LABD icon
96
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
– –
-125,000
Closed -$27.2M
ARYD
97
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-750,000
Closed -$10.3M
VINCU
98
DELISTED
Vincerx Pharma, Inc. Unit
VINCU
– –
-300,000
Closed -$8.1M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Boxer Capital held 98 positions worth $2.83B, down 3.9% from $2.95B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital deployed $174M of net new capital in Q2 2021, opening 13 new positions and adding to 2 existing holdings. Its largest new stake was Biomea Fusion: 2,088,405 shares worth $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Achilles Therapeutics, an estimated $2.6K trimmed.

  • Boxer Capital's largest Q2 2021 buy was Biomea Fusion: 2,088,405 shares worth $32.6M.
  • Boxer Capital added most to POINT Biopharma Global Inc. Common Stock in Q2 2021, an estimated $10.2M increase.
  • Boxer Capital's biggest Q2 2021 reduction was Achilles Therapeutics, cutting an estimated $2.6K.
  • Boxer Capital fully exited Direxion Daily S&P Biotech Bear 3X ETF in Q2 2021, selling an estimated $27.2M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.83B portfolio in Q2 2021.
  • Boxer Capital opened 13 new positions and closed 3 in Q2 2021.
  • Boxer Capital's portfolio value fell 3.9% quarter-over-quarter to $2.83B.

Based on Boxer Capital's 13F filing for Q2 2021, filed 16 Aug 2021.